logo
logo
logo
logo
  • News
  • Approach
  • ESG
  • Portfolio
  • Team
  • Tech Investments
  • Contact

Month: September 2019

STipe Therapeutics launches with EUR 20 million Series A financing

STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, launched today with an EUR 20 million Series A financing. The round was co-led by Novo Holdings and Arix Bioscience plc who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S.


by eazee-designstudio

AMBOSS raises €30M in Series B

AMBOSS has secured €30 million in Series B funding led by Partech’s growth fund, with Target Global acting as a co-investor. Existing investors Cherry Ventures, Wellington Partners and Holtzbrinck Digital also participated in the new financing round. With the new funding, AMBOSS will accelerate the global rollout of its knowledge platform and further invest in its smart guidance application to improve daily clinical decision-making for both generalist and specialist doctors.


by eazee-designstudio

iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets

iOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg is designed to broadly screen tumor cells for hijacked immune checkpoints, which enable targeting of the tumor´s immune resistance mechanisms.


by eazee-designstudio

Adrenomed completes full enrollment with 300 patients in AdrenOSS-2 trial with Adrecizumab in septic shock

Adrenomed announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in life-threatening conditions associated with vascular leakage, congestion and shock.


by eazee-designstudio

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design.


by eazee-designstudio

Themis raises EUR 40 Million in Series D financing round backed by US/EU consortium

Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million). The proceeds from this Series D round will be used to accelerate the company’s pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board.


by eazee-designstudio

Recent Posts

  • Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
  • ImCheck Appoints Thomas Civik as Independent Chairman of the Board
  • Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
  • Carisma Therapeutics Closes Merger with Sesen Bio
  • Confo Therapeutics Announces Global Licensing Agreement With Lilly For Peripheral Pain Candidate, CFTX-1554

Archives

  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
  • September 2021
  • August 2021
  • June 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • November 2018
  • October 2018
  • September 2018
  • June 2018
  • March 2018
  • February 2018
  • January 2018
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • June 2017
  • May 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • June 2016
  • May 2016

Categories

  • Wellington Partners
  • Portfolio News

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

© 2022 Wellington Partners. All rights reserved  |  Imprint  |  Privacy Policy | SFDR Disclosures | PRIIPS

Privacy Preference Center

Privacy Preferences